Opko Health Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost bought 4,300 shares of Opko Health stock in a transaction dated Wednesday, November 23rd. The shares were acquired at an average cost of $10.09 per share, for a total transaction of $43,387.00. Following the completion of the purchase, the chief executive officer now directly owns 3,068,951 shares of the company’s stock, valued at approximately $30,965,715.59. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Phillip Md Et Al Frost also recently made the following trade(s):

  • On Tuesday, November 22nd, Phillip Md Et Al Frost purchased 5,400 shares of Opko Health stock. The stock was purchased at an average cost of $10.28 per share, for a total transaction of $55,512.00.
  • On Monday, November 21st, Phillip Md Et Al Frost purchased 3,600 shares of Opko Health stock. The stock was purchased at an average cost of $10.41 per share, for a total transaction of $37,476.00.
  • On Friday, November 18th, Phillip Md Et Al Frost purchased 1,800 shares of Opko Health stock. The stock was purchased at an average cost of $10.38 per share, for a total transaction of $18,684.00.
  • On Wednesday, November 16th, Phillip Md Et Al Frost purchased 4,300 shares of Opko Health stock. The stock was purchased at an average cost of $10.13 per share, for a total transaction of $43,559.00.
  • On Friday, November 11th, Phillip Md Et Al Frost purchased 14,600 shares of Opko Health stock. The stock was purchased at an average cost of $9.46 per share, for a total transaction of $138,116.00.
  • On Wednesday, November 9th, Phillip Md Et Al Frost purchased 5,400 shares of Opko Health stock. The stock was purchased at an average cost of $9.33 per share, for a total transaction of $50,382.00.
  • On Tuesday, November 8th, Phillip Md Et Al Frost purchased 23,100 shares of Opko Health stock. The stock was purchased at an average cost of $9.22 per share, for a total transaction of $212,982.00.
  • On Wednesday, November 2nd, Phillip Md Et Al Frost purchased 10,000 shares of Opko Health stock. The stock was purchased at an average cost of $9.48 per share, for a total transaction of $94,800.00.
  • On Tuesday, November 1st, Phillip Md Et Al Frost purchased 10,000 shares of Opko Health stock. The stock was purchased at an average cost of $9.49 per share, for a total transaction of $94,900.00.
  • On Monday, October 31st, Phillip Md Et Al Frost purchased 11,800 shares of Opko Health stock. The stock was purchased at an average cost of $9.43 per share, for a total transaction of $111,274.00.

Opko Health Inc. (NASDAQ:OPK) opened at 10.83 on Monday. The firm has a 50-day moving average price of $9.74 and a 200-day moving average price of $9.88. Opko Health Inc. has a 12-month low of $7.12 and a 12-month high of $11.85. The company’s market cap is $6.04 billion.

Opko Health (NASDAQ:OPK) last announced its quarterly earnings results on Monday, November 7th. The company reported ($0.03) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.03). Opko Health had a negative return on equity of 0.49% and a negative net margin of 0.81%. The business had revenue of $298 million for the quarter, compared to the consensus estimate of $322 million. During the same period last year, the business posted $0.25 EPS. The business’s revenue was up 108.4% compared to the same quarter last year. On average, analysts forecast that Opko Health Inc. will post ($0.08) earnings per share for the current fiscal year.

Insider Buying and Selling by Quarter for Opko Health (NASDAQ:OPK)

COPYRIGHT VIOLATION NOTICE: This report was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this report on another website, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The legal version of this report can be accessed at https://www.thecerbatgem.com/2016/11/28/opko-health-inc-opk-ceo-phillip-md-et-al-frost-purchases-4300-shares-of-stock-2.html.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Whalerock Point Partners LLC bought a new position in shares of Opko Health during the third quarter worth about $2,100,000. Piedmont Investment Advisors LLC bought a new position in shares of Opko Health during the third quarter worth about $622,000. Price T Rowe Associates Inc. MD increased its position in shares of Opko Health by 3.1% in the third quarter. Price T Rowe Associates Inc. MD now owns 947,871 shares of the company’s stock worth $10,038,000 after buying an additional 28,700 shares in the last quarter. Finally, LPL Financial LLC increased its position in shares of Opko Health by 3.9% in the third quarter. LPL Financial LLC now owns 13,374 shares of the company’s stock worth $142,000 after buying an additional 504 shares in the last quarter. Institutional investors and hedge funds own 22.27% of the company’s stock.

A number of research analysts have recently issued reports on the company. TheStreet downgraded Opko Health from a “hold” rating to a “sell” rating in a report on Wednesday, November 9th. Zacks Investment Research raised Opko Health from a “sell” rating to a “hold” rating in a report on Tuesday, October 25th. Oppenheimer Holdings Inc. reaffirmed a “hold” rating on shares of Opko Health in a report on Monday, October 10th. Jefferies Group reaffirmed a “hold” rating and set a $10.00 price target on shares of Opko Health in a report on Monday, October 10th. Finally, JPMorgan Chase & Co. set a $14.00 price target on Opko Health and gave the company a “buy” rating in a report on Tuesday, August 9th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $13.17.

About Opko Health

OPKO Health, Inc (OPKO) is a healthcare company. The Company operates through two segments: diagnostics and pharmaceutical. The pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, and its pharmaceutical research and development operations. The diagnostics segment primarily consists of its clinical laboratory operations.

5 Day Chart for NASDAQ:OPK

Receive News & Stock Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related stocks with our FREE daily email newsletter.